Cargando…

Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis

BACKGROUND: The prevalence of tree nut allergy has increased worldwide, and cashew has become one of the most common food allergens. More critically, cashew allergy is frequently associated with severe anaphylaxis. Despite the high medical need, no approved treatment is available and strict avoidanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelletier, Benjamin, Perrin, Audrey, Assoun, Noémie, Plaquet, Camille, Oreal, Nathalie, Gaulme, Laetitia, Bouzereau, Adeline, Labernardière, Jean‐Louis, Ligouis, Mélanie, Dioszeghy, Vincent, Wavrin, Sophie, Matthews, Katie, Porcheray, Fabrice, Sampson, Hugh A., Hervé, Pierre‐Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246921/
https://www.ncbi.nlm.nih.gov/pubmed/32996148
http://dx.doi.org/10.1111/all.14605
_version_ 1783716412654616576
author Pelletier, Benjamin
Perrin, Audrey
Assoun, Noémie
Plaquet, Camille
Oreal, Nathalie
Gaulme, Laetitia
Bouzereau, Adeline
Labernardière, Jean‐Louis
Ligouis, Mélanie
Dioszeghy, Vincent
Wavrin, Sophie
Matthews, Katie
Porcheray, Fabrice
Sampson, Hugh A.
Hervé, Pierre‐Louis
author_facet Pelletier, Benjamin
Perrin, Audrey
Assoun, Noémie
Plaquet, Camille
Oreal, Nathalie
Gaulme, Laetitia
Bouzereau, Adeline
Labernardière, Jean‐Louis
Ligouis, Mélanie
Dioszeghy, Vincent
Wavrin, Sophie
Matthews, Katie
Porcheray, Fabrice
Sampson, Hugh A.
Hervé, Pierre‐Louis
author_sort Pelletier, Benjamin
collection PubMed
description BACKGROUND: The prevalence of tree nut allergy has increased worldwide, and cashew has become one of the most common food allergens. More critically, cashew allergy is frequently associated with severe anaphylaxis. Despite the high medical need, no approved treatment is available and strict avoidance and preparedness for prompt treatment of allergic reactions are considered dual standard of care. In the meantime, Phase III study results suggest investigational epicutaneous immunotherapy (EPIT) may be a relevant and safe treatment for peanut allergy and may improve the quality of life for many peanut allergic children. OBJECTIVE: We aimed to evaluate the capacity of EPIT to provide protection against cashew‐induced anaphylaxis in a relevant mouse model. METHODS: The efficacy of EPIT was evaluated by applying patches containing cashew allergens to cashew‐sensitized mice. As negative control, sham mice received patches containing excipient. Following treatment, mice were challenged orally to cashew and anaphylactic symptoms, as well as plasmatic levels of mast‐cell proteases (mMCP)‐1/7, were quantified. RESULTS: Of 16 weeks of EPIT significantly protects against anaphylaxis by promoting a faster recovery of challenged mice. This protection was characterized by a significant reduction of temperature drop and clinical symptoms, 60 minutes after challenge. This was associated with a decrease in mast‐cell reactivity as attested by the reduction of mMCP‐1/7 in plasma, suggesting that EPIT specifically decrease IgE‐mediated anaphylaxis. CONCLUSION: We demonstrate that EPIT markedly reduced IgE‐mediated allergic reactions in a mouse model of cashew allergy, which suggests that EPIT may be a relevant approach to treating cashew allergy.
format Online
Article
Text
id pubmed-8246921
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82469212021-07-02 Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis Pelletier, Benjamin Perrin, Audrey Assoun, Noémie Plaquet, Camille Oreal, Nathalie Gaulme, Laetitia Bouzereau, Adeline Labernardière, Jean‐Louis Ligouis, Mélanie Dioszeghy, Vincent Wavrin, Sophie Matthews, Katie Porcheray, Fabrice Sampson, Hugh A. Hervé, Pierre‐Louis Allergy ORIGINAL ARTICLES BACKGROUND: The prevalence of tree nut allergy has increased worldwide, and cashew has become one of the most common food allergens. More critically, cashew allergy is frequently associated with severe anaphylaxis. Despite the high medical need, no approved treatment is available and strict avoidance and preparedness for prompt treatment of allergic reactions are considered dual standard of care. In the meantime, Phase III study results suggest investigational epicutaneous immunotherapy (EPIT) may be a relevant and safe treatment for peanut allergy and may improve the quality of life for many peanut allergic children. OBJECTIVE: We aimed to evaluate the capacity of EPIT to provide protection against cashew‐induced anaphylaxis in a relevant mouse model. METHODS: The efficacy of EPIT was evaluated by applying patches containing cashew allergens to cashew‐sensitized mice. As negative control, sham mice received patches containing excipient. Following treatment, mice were challenged orally to cashew and anaphylactic symptoms, as well as plasmatic levels of mast‐cell proteases (mMCP)‐1/7, were quantified. RESULTS: Of 16 weeks of EPIT significantly protects against anaphylaxis by promoting a faster recovery of challenged mice. This protection was characterized by a significant reduction of temperature drop and clinical symptoms, 60 minutes after challenge. This was associated with a decrease in mast‐cell reactivity as attested by the reduction of mMCP‐1/7 in plasma, suggesting that EPIT specifically decrease IgE‐mediated anaphylaxis. CONCLUSION: We demonstrate that EPIT markedly reduced IgE‐mediated allergic reactions in a mouse model of cashew allergy, which suggests that EPIT may be a relevant approach to treating cashew allergy. John Wiley and Sons Inc. 2020-10-23 2021-04 /pmc/articles/PMC8246921/ /pubmed/32996148 http://dx.doi.org/10.1111/all.14605 Text en © 2020 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle ORIGINAL ARTICLES
Pelletier, Benjamin
Perrin, Audrey
Assoun, Noémie
Plaquet, Camille
Oreal, Nathalie
Gaulme, Laetitia
Bouzereau, Adeline
Labernardière, Jean‐Louis
Ligouis, Mélanie
Dioszeghy, Vincent
Wavrin, Sophie
Matthews, Katie
Porcheray, Fabrice
Sampson, Hugh A.
Hervé, Pierre‐Louis
Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis
title Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis
title_full Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis
title_fullStr Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis
title_full_unstemmed Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis
title_short Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis
title_sort epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246921/
https://www.ncbi.nlm.nih.gov/pubmed/32996148
http://dx.doi.org/10.1111/all.14605
work_keys_str_mv AT pelletierbenjamin epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis
AT perrinaudrey epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis
AT assounnoemie epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis
AT plaquetcamille epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis
AT orealnathalie epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis
AT gaulmelaetitia epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis
AT bouzereauadeline epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis
AT labernardierejeanlouis epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis
AT ligouismelanie epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis
AT dioszeghyvincent epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis
AT wavrinsophie epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis
AT matthewskatie epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis
AT porcherayfabrice epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis
AT sampsonhugha epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis
AT hervepierrelouis epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis